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ing genes. The quality of the different papers varies, and
although some of them are only descriptions of findings of
different genetic alterations in small series with no emphasis
on the title 'Targets for Therapy', the overall impression of
the book is good. Many of the papers point to the dawning
potential of oncogenes and their products as targets for
specific therapy, and this is exciting reading.
In the first section the epidermal growth-factor receptor
homologue c-erbB-2 is the subject of most papers. The first
paper gives a very good overview of the involvement of this
receptor in human malignant diseases, and its role in the
biology of human cancer. Production of humanised mono-
clonal antibodies directed against the extra cellular domain
of c-erbB-2, their antiproliferative effects on cultured tumour
cell lines and on tumour xenografts seem very promising for
the use of this agent in treatment ofcancers involving overex-
pression of this receptor. Clinical trials have started on both
breast and ovarian cancer patients. Other strategies where
antibodies to c-erbB-2 are coupled to a variety of toxins,
drugs or isotopes are also considered in the following papers.
They also show the importance of the epitope the antibody
recognise in order to be effective in growth inhibition.
Monoclonal antibodies against the EGF receptor also seem
to be clinically useful both for radio-imaging and for
therapeutic applications. These antibodies seem to act as
antagonists of EGF, and such antibodies are now also used
in clinical trials. The last paper in this section deals with the
growing family of fibroblast growth factors (FGFs) and their
receptors as possible targets for therapy. More recent
experiments, unfortunately not included in the book, indicate
that both FGFs and pleiotrophins are likely to be important
in tumour angiogenesis. Antibodies to FGF have been
coupled to toxins and have shown potential anti-cancer
activity toward human breast cancers growing in nude mice.
Section two deals with intracellular oncogene products as
targets for therapy, and particularly the ras oncoproteins.
This section is in my opinion the most exciting and best
written part of the book. The first paper in this section gives
an excellent overview of the mechanisms whereby intracel-
lular antigens reach and can be seen by the host's immune
system, and sets the framework on which therapeutic strat-
egies can be devised. It contains illustrating figures explaining
MHC class I and class II pathways, preparing the reader for
the following papers. The overview of the ras oncogenes and
their clinical potentials in the next chapter gives an excellent
description of the ras signal transduction pathway, and ras
activation in tumorigenesis, diagnosis and prognosis. Poten-
tial strategies for reverting ras transformation are outlined.
This is further explored in chapter 14 where antisense
oligonucleotide and ribozyme technology against ras are des-
cribed; and in chapter 15 where prospects for anti-ras
chemotherapy are covered, showing that the ras-processing
enzymes involved in farnesylation and prenylation are possi-
ble targets for therapy. The frequent occurrence of ras muta-
tions in a range of human malignancies has made the
identification of pharmacological agents that block the func-
tion of the oncogenic ras an important and exciting pos-
sibility in therapy. Mutant ras oncogenes may also be targets
for immunotherapy as discussed in chapter 12 and 13. Other
oncoproteins such as the nuclear proteins myc and jun have
to be much more understood both at the structural and
functional level before they can be used as targets for
therapy, but when this information becomes available they
will surely expand opportunities for pharmaceutical interven-
tion in growth control.
The third section deals with tumour suppressor genes and
immortalising genes. This is the newest scenario of genes
found to be involved in tumorigenesis. However, none of the
papers points to any possibility of using these as targets for
therapy. The function of some of these proteins (both the
normal and mutated counterpart) is today fairly well known,
and should have been included to give the reader a possibility
to associate where in the pathways a possible therapy could
be directed. As a review of tumour suppressor genes and
their involvement in human cancers these papers are too
limited to give the reader an updated knowledge.
Altogether the book is exciting reading and leaves the
reader with an optimism that there are great new potentials
in using gene therapy for treatment of cancer.
A.-L. B0rresen
Handbook of Psychooncology
Edited by J.C. Holland & J.H. Rowland, Oxford: OUP,
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Psycho-oncology is a new and rapidly expanding field in both
research and clinical practice. This comprehensive text book
is a welcome contribution, since much of the relevant
literature has been scattered in Oncological and Psycho-
logical Journals over recent years, making it difficult to
assimulate the extensive, available, published material.
The Handbook is wide ranging, drawing on cultural,
psychological and medical aspects of cancer that contribute
to adjustment, as well as special problems posed, for exam-
ple, by cancer in children or in the elderly. It gives detailed
and practical information on important specific areas, includ-
ing principle treatment modalities, cancer sites, significant
adverse effects, psychiatric disorder and sexual dysfunction
and covers a wide range of therapeutic interventions. In
addition, problems for families and staff are reviewed and
chapters on ethics and bereavement find their place. A
notable exclusion is a detailed appraisal of training in com-
munication and counselling skills for health care profes-
sionals working in Oncology, and somewhat brief coverage is
given to important topics such as stress and cancer, and
quality of life research.
The authors unashamedly draw on American research and
clinical practice for this book, but this creates some
imbalance in representing research in the field. Equally, not
all aspects of clinical management in psycho-oncology are
relevant to British Oncology Services, where there are very
few liaison psychiatrists and where the psychotropic drugs
suggested may not be available. Fortunately, other briefer
texts for the British market fill these gaps (such as 'Counsell-
ing and Communication in Health Care' edited by H. Davis
and L. Fallowfield and 'Cancer Patient Care: Psychological
Treatments' edited by M. Watson).
A strength of this Handbook is the integration of research
data to support guidelines in clinical management, although
the layout results in some splitting of information through a
range of different chapters. Good cross-referencing reduces
the frustration of this, but for topics such as depression,
major chapters covering all aspects might have been more
convenient.
This Handbook will undoubtedly become a standard
reference text for this field and the paperback edition
represents good value for the Library of any Hospital where
oncology services are provided. It will appeal to all the
disciplines involved in cancer care because of its wide
coverage, but is a readable text that has something to offer to
the expert as well as the novice.
P. Hopwood
Metastasis: Basic Research and its Clinical Applications
Edited by H. Rabes, P.E. Peters & K. Munk, Basel: Karger,
1992, 394pp. £34.40.
This book reports the proceedings of a Symposium held in
1991 under the auspices of a German Foundation. The
Scheel-Stiftung, according to the preface, is a private Found-
ation which supports cancer research and holds periodic
meetings on different aspects of cancer research. The objec-
tive of the organisers was to bring together theoretical, exper-
imental and clinical research related to metastasis. In its aims
this Symposium resembles many others that have gone before
it. This book suffers, like so many publications of conference